{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T18:27:21Z","timestamp":1793212041264,"version":"4.5.0"},"reference-count":109,"publisher":"Wiley","issue":"7","license":[{"start":{"date-parts":[[2022,8,3]],"date-time":"2022-08-03T00:00:00Z","timestamp":1659484800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Andrology"],"published-print":{"date-parts":[[2022,10]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Background<\/jats:title><jats:p>Dermatologic medications have been linked to issues with safety during pregnancy and lactation. Despite this, limited research, often with conflicting findings, has been published on the association between dermatologic medications, male infertility, sexual dysfunction and teratogenicity following paternal exposure.<\/jats:p><\/jats:sec><jats:sec><jats:title>Objective<\/jats:title><jats:p>This review seeks to provide evidence\u2010based guidance for physicians who are prescribing dermatologic medications to male patients who are trying to conceive.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>Common medications used in the largest outpatient specialist dermatologic centre in Singapore were the focus of this review. A PubMed search using MeSH terms from inception to April 22, 2021, was conducted. A secondary search was conducted to include common non\u2010dermatologic medications. Drug information from various online clinical resources and the Tenth Edition of Drugs in Pregnancy and Lactation was also used as a reference.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>In this review of 234 studies, 131 medications were covered. A total of 34 medications were associated with male infertility and sexual dysfunction, while 16 medications were implicated with concerns of teratogenicity.<\/jats:p><\/jats:sec><jats:sec><jats:title>Discussion and conclusion<\/jats:title><jats:p>Physicians are advised to discuss the potential impact on male fertility and teratogenicity with males who are trying to conceive while taking into consideration the clinical efficacy and tolerability of these medications and alternative treatments.<\/jats:p><\/jats:sec>","DOI":"10.1111\/andr.13236","type":"journal-article","created":{"date-parts":[[2022,7,25]],"date-time":"2022-07-25T13:54:10Z","timestamp":1658757250000},"page":"1272-1285","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Review of dermatologic medications and impact on male fertility, sexual dysfunction and teratogenicity"],"prefix":"10.1111","volume":"10","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1948-7213","authenticated-orcid":false,"given":"Edward XW","family":"Hui","sequence":"first","affiliation":[{"name":"National Skin Centre  Singapore"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoling","family":"Huang","sequence":"additional","affiliation":[{"name":"National Skin Centre  Singapore"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hazel H.","family":"Oon","sequence":"additional","affiliation":[{"name":"National Skin Centre  Singapore"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2022,8,3]]},"reference":[{"key":"e_1_2_10_2_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijwd.2019.05.002"},{"key":"e_1_2_10_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2013.09.010"},{"key":"e_1_2_10_4_1","first-page":"21","article-title":"Update on biologic safety for patients with psoriasis during pregnancy. International journal of women's","volume":"3","author":"Porter ML","year":"2017","journal-title":"Dermatology"},{"key":"e_1_2_10_5_1","unstructured":"IBM Micromedex Solutions. Acetaminophen. Accessed October 1 2021.http:\/\/micromedex.com\/"},{"key":"e_1_2_10_6_1","doi-asserted-by":"publisher","DOI":"10.1111\/and.12874"},{"key":"e_1_2_10_7_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.41191"},{"key":"e_1_2_10_8_1","first-page":"77","article-title":"Paternal safety of anti\u2010rheumatic medications. Best practice & research","volume":"64","author":"Bermas BL","year":"2020","journal-title":"Clin Obstetrics Gynaecol"},{"key":"e_1_2_10_9_1","first-page":"211","article-title":"Plasma testosterone levels in heroin addiction and during methadone maintenance","volume":"192","author":"Mendelson JH","year":"1975","journal-title":"J\u00a0Pharmacol Exp Ther"},{"key":"e_1_2_10_10_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjmed.2012.12.001"},{"key":"e_1_2_10_11_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2019.03.043"},{"key":"e_1_2_10_12_1","doi-asserted-by":"publisher","DOI":"10.3233\/JRS-180744"},{"key":"e_1_2_10_13_1","unstructured":"ACCUTANE (Isotretinoin) [Package Insert].Roche Laboratories Inc.;2008."},{"key":"e_1_2_10_14_1","doi-asserted-by":"publisher","DOI":"10.1002\/tera.1420330315"},{"key":"e_1_2_10_15_1","doi-asserted-by":"publisher","DOI":"10.1080\/09546634.2016.1202402"},{"key":"e_1_2_10_16_1","doi-asserted-by":"publisher","DOI":"10.1111\/dth.12069"},{"key":"e_1_2_10_17_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2018.10.023"},{"key":"e_1_2_10_18_1","first-page":"12","article-title":"Adverse sexual effects of treatment with finasteride or dutasteride for male androgenetic alopecia: a systematic review and meta\u2010analysis","volume":"99","author":"Lee S","year":"2019","journal-title":"Acta Derm Venereol"},{"key":"e_1_2_10_19_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2018.09.031"},{"key":"e_1_2_10_20_1","doi-asserted-by":"publisher","DOI":"10.1007\/s12020-018-1593-5"},{"key":"e_1_2_10_21_1","doi-asserted-by":"publisher","DOI":"10.1177\/1557988314538445"},{"key":"e_1_2_10_22_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2012.4488"},{"key":"e_1_2_10_23_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.fertnstert.2019.11.030"},{"key":"e_1_2_10_24_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ynstr.2019.100209"},{"key":"e_1_2_10_25_1","doi-asserted-by":"publisher","DOI":"10.1111\/1346-8138.14329"},{"key":"e_1_2_10_26_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1695-4033(04)78429-5"},{"key":"e_1_2_10_27_1","volume-title":"Prescribing information","author":"Propecia (Finasteride)","year":"2014"},{"key":"e_1_2_10_28_1","doi-asserted-by":"publisher","DOI":"10.1111\/dth.13379"},{"key":"e_1_2_10_29_1","volume-title":". Dutasteride: drug information","author":"UpToDate, Inc"},{"key":"e_1_2_10_30_1","unstructured":"IBM Micromedex Solutions.Minoxidil. Accessed October 1 2021.http:\/\/micromedex.com\/"},{"key":"e_1_2_10_31_1","first-page":"23","article-title":"Topical minoxidil 5% induced male sexual dysfunction","volume":"4","author":"Al Zo'ubi M","year":"2017","journal-title":"Ind J Med Res Pharm Sci"},{"key":"e_1_2_10_32_1","unstructured":"IBM Micromedex Solutions.Onabotulinumtoxin A. Accessed October 1 2021.http:\/\/micromedex.com\/"},{"key":"e_1_2_10_33_1","unstructured":"DermNet NZ.Fluorouracil cream.https:\/\/dermnetnz.org\/topics\/5-fluorouracil-cream"},{"key":"e_1_2_10_34_1","unstructured":"DermNet NZ.Keloid and hypertrophic scar.https:\/\/dermnetnz.org\/topics\/keloid-and-hypertrophic-scar"},{"key":"e_1_2_10_35_1","unstructured":"IBM Micromedex Solutions. Clobetasol propionate. Accessed October 1 2021.http:\/\/micromedex.com\/"},{"key":"e_1_2_10_36_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2020.02.044"},{"key":"e_1_2_10_37_1","doi-asserted-by":"publisher","DOI":"10.1111\/ajd.12641"},{"key":"e_1_2_10_38_1","unstructured":"IBM Micromedex Solutions. Minocycline. Accessed October 1 2021.http:\/\/micromedex.com\/"},{"key":"e_1_2_10_39_1","doi-asserted-by":"publisher","DOI":"10.2165\/00003088-198815060-00001"},{"key":"e_1_2_10_40_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2015.12.037"},{"key":"e_1_2_10_41_1","unstructured":"IBM Micromedex Solutions. Clofazimine. Accessed October 1 2021.http:\/\/micromedex.com\/"},{"key":"e_1_2_10_42_1","volume-title":"Drugs in pregnancy and lactation: a reference guide to fetal and neonatal risk","author":"Briggs GG","year":"2014"},{"key":"e_1_2_10_43_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(78)92243-2"},{"key":"e_1_2_10_44_1","unstructured":"IBM Micromedex Solutions. Metronidazole. Accessed October 1 2021.http:\/\/micromedex.com\/"},{"key":"e_1_2_10_45_1","unstructured":"IBM Micromedex Solutions. Dapsone. Accessed October 1 2021.http:\/\/micromedex.com\/"},{"key":"e_1_2_10_46_1","unstructured":"IBM Micromedex Solutions. Clindamycin. Accessed October 1 2021.http:\/\/micromedex.com\/"},{"key":"e_1_2_10_47_1","unstructured":"IBM Micromedex Solutions. Erythromycin. Accessed October 1 2021.http:\/\/micromedex.com\/"},{"key":"e_1_2_10_48_1","unstructured":"IBM Micromedex Solutions. Clarithromycin. Accessed October 1 2021.http:\/\/micromedex.com\/"},{"key":"e_1_2_10_49_1","unstructured":"IBM Micromedex Solutions. Rifampicin. Accessed October 1 2021.http:\/\/micromedex.com\/"},{"key":"e_1_2_10_50_1","unstructured":"IBM Micromedex Solutions. Griseofulvin. Accessed October 1 2021.http:\/\/micromedex.com\/"},{"key":"e_1_2_10_51_1","doi-asserted-by":"publisher","DOI":"10.1002\/j.1939-4640.1992.tb00298.x"},{"key":"e_1_2_10_52_1","doi-asserted-by":"publisher","DOI":"10.1001\/archinte.1982.00340250097015"},{"key":"e_1_2_10_53_1","unstructured":"IBM Micromedex Solutions. Ketoconazole. Accessed October 1 2021.http:\/\/micromedex.com\/"},{"key":"e_1_2_10_54_1","first-page":"636","article-title":"Effect of fluconazole on the fertility of male rabbits","volume":"52","author":"el\u2010Medany AH","year":"2002","journal-title":"Arzneimittel\u2010Forschung"},{"key":"e_1_2_10_55_1","unstructured":"IBM Micromedex Solutions. Terbinafine. Accessed October 1 2021.http:\/\/micromedex.com\/"},{"key":"e_1_2_10_56_1","unstructured":"IBM Micromedex Solutions. Valacyclovir. Accessed October 1 2021.http:\/\/micromedex.com\/"},{"key":"e_1_2_10_57_1","first-page":"259","article-title":"Effect of malathion on reproductive system of male rats","volume":"29","author":"Choudhary N","year":"2008","journal-title":"J\u00a0Environ Biol"},{"key":"e_1_2_10_58_1","unstructured":"IBM Micromedex Solutions. Albendazole. Accessed October 1 2021.http:\/\/micromedex.com\/"},{"key":"e_1_2_10_59_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0890-6238(01)00118-6"},{"key":"e_1_2_10_60_1","doi-asserted-by":"publisher","DOI":"10.1001\/archderm.1991.01680030067008"},{"key":"e_1_2_10_61_1","unstructured":"IBM Micromedex Solutions. Calcipotriene. Accessed October 1 2021.http:\/\/micromedex.com\/"},{"key":"e_1_2_10_62_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.semarthrit.2018.07.011"},{"key":"e_1_2_10_63_1","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2011-200299"},{"key":"e_1_2_10_64_1","doi-asserted-by":"publisher","DOI":"10.1111\/andr.12366"},{"key":"e_1_2_10_65_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.fertnstert.2004.11.068"},{"key":"e_1_2_10_66_1","doi-asserted-by":"publisher","DOI":"10.2174\/1574886314666190726155147"},{"key":"e_1_2_10_67_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2017.05.025"},{"key":"e_1_2_10_68_1","unstructured":"IBM Micromedex Solutions. Brodalumab. Accessed October 1 2021.http:\/\/micromedex.com\/"},{"key":"e_1_2_10_69_1","unstructured":"IBM Micromedex Solutions. Guselkumab. Accessed October 1 2021.http:\/\/micromedex.com\/"},{"key":"e_1_2_10_70_1","unstructured":"IBM Micromedex Solutions. Risankizumab. Accessed October 1 2021.http:\/\/micromedex.com\/"},{"key":"e_1_2_10_71_1","unstructured":"IBM Micromedex Solutions. Omalizumab. Accessed October 1 2021.http:\/\/micromedex.com\/"},{"key":"e_1_2_10_72_1","first-page":"277","article-title":"New systemic agents in dermatology with respect to fertility, pregnancy, and lactation","volume":"13","author":"Grunewald S","year":"2015","journal-title":"J\u00a0German Soc Dermatol"},{"key":"e_1_2_10_73_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2010-07-295444"},{"key":"e_1_2_10_74_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2018.11.057"},{"key":"e_1_2_10_75_1","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/kev404"},{"key":"e_1_2_10_76_1","doi-asserted-by":"publisher","DOI":"10.1177\/1759720X19899296"},{"key":"e_1_2_10_77_1","unstructured":"IBM Micromedex Solutions. Baricitinib. Accessed October 1 2021.http:\/\/micromedex.com\/"},{"key":"e_1_2_10_78_1","unstructured":"IBM Micromedex Solutions.Upadacitinib. Accessed October 1 2021.http:\/\/micromedex.com\/"},{"key":"e_1_2_10_79_1","unstructured":"IBM Micromedex Solutions.Tofacitinib. Accessed October 1 2021.http:\/\/micromedex.com\/"},{"key":"e_1_2_10_80_1","unstructured":"IBM Micromedex Solutions.Apremilast. Accessed October 1 2021.http:\/\/micromedex.com\/"},{"key":"e_1_2_10_81_1","unstructured":"IBM Micromedex Solutions.Cyclophosphamide. Accessed October 1 2021.http:\/\/micromedex.com\/"},{"key":"e_1_2_10_82_1","unstructured":"IBM Micromedex Solutions.Hydroxyurea. Accessed October 1 2021.http:\/\/micromedex.com\/"},{"key":"e_1_2_10_83_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1445-5994.2006.01290.x"},{"key":"e_1_2_10_84_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2020.09.006"},{"key":"e_1_2_10_85_1","unstructured":"IBM Micromedex Solutions.Mycophenolate mofetil. Accessed October 1 2021.http:\/\/micromedex.com\/"},{"key":"e_1_2_10_86_1","first-page":"1355","article-title":"Thalidomide is distributed into human semen after oral dosing","volume":"29","author":"Teo SK","year":"2001","journal-title":"Drug Metab Dispos"},{"key":"e_1_2_10_87_1","unstructured":"IBM Micromedex Solutions.Thalidomide. Accessed October 1 2021.http:\/\/micromedex.com\/"},{"key":"e_1_2_10_88_1","doi-asserted-by":"publisher","DOI":"10.1093\/humupd\/dmx034"},{"key":"e_1_2_10_89_1","first-page":"448","article-title":"Impregnate occasion for male renal transplant recipients","volume":"14","author":"Xu LG","year":"2008","journal-title":"Nat J Androl"},{"key":"e_1_2_10_90_1","doi-asserted-by":"publisher","DOI":"10.1111\/and.12477"},{"key":"e_1_2_10_91_1","doi-asserted-by":"publisher","DOI":"10.1159\/000475121"},{"key":"e_1_2_10_92_1","doi-asserted-by":"publisher","DOI":"10.1093\/humrep\/13.2.360"},{"key":"e_1_2_10_93_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1610-0387.2007.06169.x"},{"key":"e_1_2_10_94_1","first-page":"1793","article-title":"Gynecomastia and sexual impotence associated with methotrexate treatment","volume":"29","author":"Aguirre MA","year":"2002","journal-title":"J\u00a0Rheumatol"},{"key":"e_1_2_10_95_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2230.2008.03082.x"},{"key":"e_1_2_10_96_1","doi-asserted-by":"publisher","DOI":"10.2340\/00015555-2714"},{"key":"e_1_2_10_97_1","unstructured":"IBM Micromedex Solutions.Methotrexate. Accessed October 1 2021.http:\/\/micromedex.com\/"},{"key":"e_1_2_10_98_1","doi-asserted-by":"publisher","DOI":"10.21037\/tau.2018.04.18"},{"key":"e_1_2_10_99_1","doi-asserted-by":"publisher","DOI":"10.3109\/15569527.2015.1119839"},{"key":"e_1_2_10_100_1","unstructured":"IBM Micromedex Solutions. Hydrocortisone. Accessed October 1 2021.http:\/\/micromedex.com\/"},{"key":"e_1_2_10_101_1","unstructured":"IBM Micromedex Solutions.Mometasone. Accessed October 1 2021.http:\/\/micromedex.com\/"},{"key":"e_1_2_10_102_1","unstructured":"IBM Micromedex Solutions.Betamethasone. Accessed October 1 2021.http:\/\/micromedex.com\/"},{"key":"e_1_2_10_103_1","unstructured":"IBM Micromedex Solutions.Pimecrolimus. Accessed October 1 2021.http:\/\/micromedex.com\/"},{"key":"e_1_2_10_104_1","unstructured":"IBM Micromedex SolutionsTazarotene. Accessed October 1 2021.http:\/\/micromedex.com\/"},{"key":"e_1_2_10_105_1","unstructured":"IBM Micromedex Solutions. Fluorouracil. Accessed October 1 2021.http:\/\/micromedex.com\/"},{"key":"e_1_2_10_106_1","unstructured":"IBM Micromedex Solutions. Azithromycin. Accessed October 1 2021.http:\/\/micromedex.com\/"},{"key":"e_1_2_10_107_1","unstructured":"IBM Micromedex Solutions. Certolizumab. Accessed October 1 2021.http:\/\/micromedex.com\/"},{"key":"e_1_2_10_108_1","unstructured":"IBM Micromedex Solutions. Secukinumab. Accessed October 1 2021.http:\/\/micromedex.com\/"},{"key":"e_1_2_10_109_1","doi-asserted-by":"publisher","DOI":"10.1111\/bcpt.12857"},{"key":"e_1_2_10_110_1","doi-asserted-by":"publisher","DOI":"10.1053\/gast.2001.28692"}],"container-title":["Andrology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/andr.13236","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/andr.13236","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/andr.13236","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,23]],"date-time":"2023-08-23T07:49:04Z","timestamp":1692776944000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/andr.13236"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,8,3]]},"references-count":109,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2022,10]]}},"alternative-id":["10.1111\/andr.13236"],"URL":"https:\/\/doi.org\/10.1111\/andr.13236","archive":["Portico"],"relation":{},"ISSN":["2047-2919","2047-2927"],"issn-type":[{"value":"2047-2919","type":"print"},{"value":"2047-2927","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,8,3]]},"assertion":[{"value":"2022-04-22","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-07-17","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-08-03","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}